Top Multiplex Assay Companies

Multiplex Assay Market size was valued at USD 4.05 Billion in 2024 and is poised to grow from USD 4.43 Billion in 2025 to USD 9.17 Billion by 2033, growing at a CAGR of 9.5% during the forecast period (2026–2033).

To increase their market presence, leading corporations are putting a variety of methods into practice, including partnerships, the introduction of cutting-edge technology & goods, and collaborations. For instance, Bio-Rad and Seegene announced their collaboration in June 2021 in order to offer molecular diagnostic testing solutions in the American market. Additionally, Qiagen introduced the NeuMoDx multiplex assay in November 2020 to offer a comprehensive selection of testing options for SARS-CoV-2 in Europe and international markets. 'Lonza Group (Switzerland)', 'DiaSorin (Italy) ', 'WuXi Biologics (China) ', 'Seegene (South Korea) ', 'Ayoxxa Biosystems (Germany) ', 'Thermo Fisher Scientific (United States) ', 'Bio-Rad Laboratories (United States) ', 'Luminex Corporation (United States) ', 'QIAGEN (Germany) ', 'Illumina (United States) ', 'Agilent Technologies (United States) ', 'PerkinElmer (United States) ', 'Merck KGaA (Germany) ', 'Becton, Dickinson and Company (United States) ', 'Roche Diagnostics (Switzerland) ', 'Siemens Healthineers (Germany) ', 'Danaher Corporation (United States) ', 'Abbott Laboratories (United States) ', 'Meso Scale Diagnostics (United States) ', 'Quanterix Corporation (United States)'

The growing demand for personalized medicine is driving the demand for multiplex assays. These assays enable the simultaneous measurement of multiple biomarkers, allowing for better patient stratification and personalized treatment options. 

Increasing adoption of multiplex immunoassays: The demand for multiplex immunoassays is increasing due to their ability to measure multiple proteins in a single sample. These assays are widely used in drug discovery, diagnostic testing, and biomarker identification.

North America dominated the global industry in 2023 and accounted for the largest share of more than 36.88% of the total revenue because of the rising R&D activities for the discovery of novel medications and diagnosis & treatment options. The region's expansion is anticipated to be fueled by the rise in government funding for the discovery of new biomarkers and the rise in the prevalence of chronic illnesses like cancer and stroke. Additionally, the presence of significant players in the region is likely to boost the rise.